Monograph

R01AC02 - Levocabastine

Propably not porphyrinogenic

Rationale

Low dose, only insignificant systemic and metabolic exposure.

Chemical description

Selective HI-antagonist used in local treatment of allergic rhinitis. Nasal spray, each dose containing 50 Âµg levocabastine. Recommended dose gives plasma concentrations in the range 2-9 Âµg/mL. Excreted in unchanged form (70%) and as glucuronide.

IPNet drug reports

Uneventful use reported in 3 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes R01A / R01AC or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands